Drug Trial Radar · NCT04400201
A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
Last checked: Nov 20, 2026Latest source record: Aug 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
330
Actual
Start
Jun 15, 2020
Primary completion
Oct 28, 2020
Study completion Oct 30, 2020
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, single-blind, active controlled, parallel group study comparing remimazolam tosilate to propofol in patients undergoing bronchoscopy.
Conditions
- Sedation
Interventions
Remimazolam TosilateDrug
Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
PropofolDrug
Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage (%) of participants who experienced successful sedation in undergoing bronchoscopy in each groupTime frame: From the onset of administration of the study drug to removal of bronchoscope on Day 1 of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.